OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

I don't think there was any use of "Oxford's technology" - where did you gleen this, robstuff?
Certainly it was "Gene therapy" but OXB doesn't own the whole lot, there are plenty of competing alternatives within the range of gene therapy... almost as many as there are genes.
The point of OXB's therapy is that the cell is one that mankind has lived with, without any recorded side-effects. Nevertheless OXB has to go through the full phase-trials, like anyone else.
The American trials whilst newsworthy (I presume) were over a year ago and it is curious that the story should come out just a few days before OXB is about to report (early Sept06, so I understand) - and is in the process of negotiating a partner that is likely to be US-based.
This (news item) couldn't have come at a better time, despite it's wholly disconnected from OXB, other than it used Gene therapy.
( I understand the story was reported on SKY, Ch5 and maybe Ch4., but it all went quiet within a short time....)
+Good luck to OXB but I would prefer my investment to be judged on PhIII trial facts rather than media excitement.
Please DYOR, this area is very complicated and the rewards are (we understand) considerable.

Anyone know what has stirred this one up this morning

Do you mean apart from the buy of 8,301,417? (9:54)

That's a fairly big spoon.

Others will follow in case they miss out!

Red

Hi Red - sorry yes it was the large buy (and a very odd amount) that caught me interest.

Ou est tout le monde?

Ya what mate

Vous etes fantome?

get in ERX now news out before RNS... no brainer

OzzMosiz - 12 Dec'06 - 11:44 - 14943 of 14945


Presenting it like this would've helped - nice find though.- I believe this is worthy of RNS

http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/12-11-2006/0004488564&EDATE=
ABOUT LY2181308 AND SURVIVIN
LY2181308 targets survivin, a molecule that supports the survival of
cells that would normally die through programmed cell death or apoptosis.
Survivin helps in the abnormal growth of cancer cells, and is abundant in
many types of cancers, including colon, brain, lung, skin and others, but
nearly nonexistent in normal cells and tissues.

-------------------------------------------------------------------------------------------------------------

http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/12-11-2006/0004488564&EDATE=
7 SURVIVIN in my patents list
Inventor: HAYES IAN (IE); COTTER TOM (IE); (+5) Applicant: EIRX THERAPEUTICS LTD (IE); HAYES IAN (IE); (+6)
EC: C07K14/47A1A; C07K14/47A33 IPC: C07K14/47; A61K38/00; C07K14/435 (+2)
Publication info: WO03091384 - 2003-11-06

-------------------------------------------------------------------------------------------------------------
CARLSBAD, Calif., Dec. 11 /PRNewswire-FirstCall/ -- Isis
Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that Eli Lilly and
Company (NYSE: LLY) highlighted two antisense oligonucleotide (ASO) drugs
in its "Update to Wall Street on Strategic Priorities and Pipeline
Progress" on Thursday. Advances with both survivin ASO (LY2181308) and
eIF-4E ASO (LY2275796) drugs were singled out among Select Early- to
Mid-Stage Pipeline Developments. Based on promising activity in early
studies, Lilly said that it is initiating Phase 2 trials for survivin ASO
in a broad range of cancers including liver cancer, prostate cancer, acute
myelogenous leukemia, ovarian cancer and non-small cell lung cancer; the
first of these trials is planned to begin this month. Lilly also said that
the Phase 1 development program for eIF-4E ASO is progressing well.
"We are pleased that Lilly includes our collaboration drugs among its
selected strategic priorities," commented C. Frank Bennett, Ph.D., Isis'
Senior Vice President of Research. "These drugs resulted from our
productive collaboration and Lilly's broad investment in antisense
technologies. We continue to work together and hope that additional drugs
will arise from our collective efforts. Lilly's progress with these
anti-cancer drugs emphasizes the broad therapeutic potential of Isis'
platform antisense technologies, and underscores our strategy of working
with partners to expand the scope of our development pipeline.

Ma foi! Un idiot-pomme de terre arrive.

OXB is now doing deals with the big boys, see news today about a deal with Glaxo!! This is great news and endorses Oxb technology as leading edge. This should just be the beginning although if they've got something big, Glaxo will probably swallow them up before that, anyone know what percentage Kingsman or the other major shareholders own?

I totally agree robstuff. But where's the sp movement (or have the last couple of week's worth of rises been due to the imminent announcement of this news?)?

I've seen this before with OXB, the rise normally comes a few days later so lets see. Anyway, great news and 2007 should be a blinder for OXB

Let's hope so

In the Biotech sector, 2007 will be a year of larger Pharmaceuticals such as AstraZeneca and Glaxo SK taking over smaller companies with developments in Phase III in the areas of oncology and neurotherapy - OXB being a prime candidate

At what take-out price? OXB has an awful lot going on at present which will be of interest to the majors.

It would have to be over double it's current price today, but next yr news and interest in the sector should take it towards a pound anyway I would think.

Patrick Evershed
Manager of New Star Select Opportunities Fund

FTSE 100 5,250 (5,500). I fear the very large Government budget deficits, record levels of personal indebtedness and dangerously large trade deficits in the USA and UK will undermine the prolonged period of economic growth and high profit margins.

If the rate of economic growth does slow and profit margins come under pressure at least some of the exceptionally highly geared private equity funds could find themselves in trouble.

Top share Oxford BioMedica could complete value enhancing deals during the year. The first could be for its lead cancer drug TroVax. The second could be for its Parkinson's treatment, which is reputed to have gone exceptionally well in pre-clinical trials, and the last is for its LentiVector drug delivery system which is in demand from other pharmaceutical companies.

Thanks both. rayrac your post backs up my view. How many OXB peers can boast a potential product pipline like that?

Oxford BioMedica and its partner Viragen Inc announced reaching a further milestone in their avian transgenics cooperation, having successfully expressed interferon alpha-2a in white eggs laid by transgenic hens.

Alpha interferon is a protein produced by the human immune system that is fundamental to the body's resistance to disease.

This is the third therapeutic protein expressed thus far in a series of 'proof-of-principle' studies, which aim to develop the OVA System (Avian Transgenic Biomanufacturing) as a large-scale biomanufacturing alternative capable of cost-effectively expressing many types of therapeutic proteins.

This latest OVA-expression study produced interferon alpha-2a, which is the active ingredient in Roferon-A, a Roche Holdings AG drug approved for the treatment of certain chronic infectious diseases and cancers.

Without wanting to sound like a policeman can I just say: Hello, hello, what's going on here then? Through the 50p barrier like it wasn't even there. Is there an announcement imminent.....?